Pediatric Pain Medication Safety in PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Pediatric personal injury patients require weight-based dosing, age-restricted medication selection, and developmental considerations that differ fundamentally from adult PI treatment. This guide covers pediatric-specific drug safety, contraindications, and documentation implications.

Pediatric pain medication management in personal injury cases requires a fundamentally different pharmacological approach than adult treatment. Children are not small adults -- their developing organ systems, immature metabolic pathways, and age-specific contraindications (Reye syndrome risk with aspirin, codeine contraindication in children under 12) create a restricted and weight-dependent medication landscape that demands pediatric-specific pharmaceutical expertise.

• Weight-based dosing is mandatory for all pediatric PI medications, with calculations typically in mg/kg, and overdose risk is significant when adult fixed-dose formulations are used without pediatric adjustment
• Aspirin and aspirin-containing products are contraindicated in children under 18 due to Reye syndrome risk (acute hepatic failure and encephalopathy associated with viral illness)
• Codeine is contraindicated in children under 12 and restricted in those 12-18 due to CYP2D6 ultra-rapid metabolizer risk producing fatal respiratory depression
• Pediatric liver and kidney immaturity (neonates and infants) and developmental changes in drug metabolism enzyme expression require age-stratified dosing approaches
• LienScripts applies pediatric dosing verification and age-based contraindication screening to all minor patients through its pharmacy lien program

Developmental Pharmacology: Why Children Metabolize Drugs Differently

Neonates and Infants (0-2 years)

Drug metabolism in neonates and infants is profoundly different from older children and adults:

• CYP450 immaturity: CYP3A4 (which metabolizes oxycodone, midazolam, and many other medications) reaches adult activity levels between 6-12 months. CYP2D6 (which activates codeine and tramadol) is variably expressed in early infancy.
• Reduced renal clearance: Neonatal GFR is approximately 2-4 mL/min (vs. adult ~120 mL/min), reaching adult values by 6-12 months. Renally cleared medications (gabapentin, morphine glucuronide metabolites) accumulate significantly.
• Higher body water percentage: Neonates are approximately 75% water vs. adult 60%, increasing the volume of distribution for water-soluble drugs and potentially reducing initial plasma concentrations.
• Reduced protein binding: Lower albumin levels mean higher free drug fractions.

Children (2-12 years)

By age 2, most metabolic pathways have matured, but pediatric-specific dosing remains essential:

• Higher metabolic rate per kg: Children often metabolize drugs faster than adults on a per-kilogram basis due to a higher liver-to-body-weight ratio. This can require relatively higher mg/kg doses to achieve therapeutic levels.
• Weight-based dosing: All medications must be dosed based on actual body weight, with maximum doses capped at adult doses regardless of weight calculation.

Adolescents (12-18 years)

Adolescents approach adult pharmacokinetics but retain some pediatric-specific risks:

• Reye syndrome risk with aspirin persists through age 18
• Codeine restrictions apply through age 18 (FDA recommendation against use in 12-18 for post-surgical pain)
• Growth plate considerations: Long-term corticosteroid use can affect growth

Specific Medication Safety Concerns

Acetaminophen: Safe But Dose-Critical

Acetaminophen is the primary analgesic and antipyretic for pediatric PI patients. Weight-based dosing is 10-15 mg/kg every 4-6 hours, with a maximum of 75 mg/kg/day (not to exceed adult maximum of 4 g/day). The hepatotoxicity risk is real in pediatric patients -- accidental overdose from combination products (acetaminophen-containing opioids plus standalone acetaminophen) is a recognized pediatric safety hazard.

NSAIDs: Ibuprofen and Naproxen

Ibuprofen is approved for children 6 months and older. Naproxen is approved for children 2 years and older. Both require weight-based dosing. Ketorolac (the injectable/short-course NSAID used for acute pain) has pediatric dosing but is limited to 5 days maximum.

Aspirin is absolutely contraindicated in all patients under 18 due to Reye syndrome -- an acute, often fatal condition involving hepatic failure and encephalopathy triggered by aspirin use during viral illness. This eliminates aspirin and aspirin-containing products from the pediatric PI toolkit entirely.

Opioids: Restricted Landscape

Codeine: Contraindicated under 12. In 2017, the FDA issued a contraindication for codeine in children under 12 for any indication. Codeine is a prodrug converted to morphine by CYP2D6. Children who are CYP2D6 ultra-rapid metabolizers convert codeine to morphine at dangerous rates, producing respiratory depression and death. Several pediatric fatalities prompted the FDA action.

Tramadol: Contraindicated under 12. Tramadol carries the same CYP2D6 ultra-rapid metabolizer risk as codeine and is contraindicated in children under 12.

Hydrocodone and oxycodone: Used with caution in children when pain severity warrants opioid therapy. Weight-based dosing with careful titration is essential. Starting doses are typically 0.1-0.2 mg/kg for oxycodone and 0.1-0.15 mg/kg for hydrocodone.

Morphine: The reference opioid in pediatric pain management. Used for moderate to severe acute pain with careful weight-based dosing (0.2-0.5 mg/kg oral, 0.1 mg/kg IV).

Muscle Relaxants: Limited Options

Most muscle relaxants lack well-established pediatric dosing and safety data. Cyclobenzaprine is not FDA-approved for children under 15. Methocarbamol, tizanidine, and carisoprodol have minimal pediatric safety data. Baclofen has established pediatric dosing for spasticity but is not a first-line acute muscle spasm medication. Diazepam has pediatric dosing for muscle spasm but carries benzodiazepine dependence and sedation concerns.

Gabapentin and Pregabalin

Gabapentin has established pediatric dosing for children 3 years and older (for seizure indications; neuropathic pain use is off-label). Weight-based dosing is 10-15 mg/kg/day divided into three doses. Pregabalin has more limited pediatric data.

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Pediatric PI medication management is defined by what you cannot prescribe as much as by what you can. The codeine and tramadol contraindications, the aspirin prohibition, the limited muscle relaxant data, and the mandatory weight-based dosing for everything create a treatment environment that requires pediatric-specific pharmaceutical expertise at every dispensing event."

Documentation Value for PI Cases

Treatment Limitation Documentation

The restricted pediatric medication landscape documents that the child's injury required pain management within a pharmacologically constrained environment. Medications that would be standard in adult PI treatment are unavailable or restricted, often meaning the child endured less effective pain control.

Weight-Based Dosing Complexity

Every medication requires individual dosing calculation based on the child's weight, with verification against maximum doses. This is not routine dispensing -- it is clinical pharmaceutical care that requires pharmacist verification at each fill.

Developmental Monitoring

Children receiving long-term medications require monitoring for developmental impact -- growth curves during corticosteroid therapy, cognitive and behavioral monitoring during opioid or gabapentin therapy, and liver/kidney function monitoring calibrated to pediatric normal ranges.

Parent/Guardian Documentation

Pediatric PI cases involve parent and guardian medication management, requiring clear instructions, liquid formulation preparation guidance, and weight-based dose verification tools. This care coordination adds documentation layers.

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For pediatric cases, the MERIT includes age-appropriate medication screening, weight-based dose verification, contraindication checks specific to the patient's age, and documentation of any pediatric-specific limitations that constrained treatment options.

What PI Attorneys Should Know

A pediatric PI patient's medication record requires interpretation through a pediatric pharmacology lens. The absence of certain medications (no codeine, no aspirin, no standard muscle relaxants) does not indicate a minor injury -- it indicates a pediatric patient whose treatment options were constrained by age-specific safety requirements. The treatment complexity lies not in the number of medications but in the expertise required to safely manage pain within the narrow pediatric therapeutic window.